Get the Stockscreener App
1.39
4.79%
-0.07
After Hours:
1.40
0.01
+0.72%
Geron Corp stock is traded at $1.39, with a volume of 12.63M.
It is down -4.79% in the last 24 hours and down -18.71% over the past month.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
See More
Previous Close:
$1.46
Open:
$1.5
24h Volume:
12.63M
Relative Volume:
0.70
Market Cap:
$891.71M
Revenue:
$183.88M
Net Income/Loss:
$-85.78M
P/E Ratio:
-10.80
EPS:
-0.1287
Net Cash Flow:
$-110.95M
1W Performance:
-12.03%
1M Performance:
-18.71%
6M Performance:
+29.91%
1Y Performance:
+10.32%
1-Day Range:
$1.38
$1.535
1-Week Range:
$1.38
$1.725
52-Week Range:
$1.04
$2.01
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.39 | 891.71M | 183.88M | -85.78M | -110.95M | -0.1287 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Sell |
| May-08-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Feb-27-25 | Downgrade | B. Riley Securities | Buy → Neutral |
| Feb-26-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
[SCHEDULE 13G/A] GERON CORP Amended Passive Investment Disclosure - Stock Titan
Geron Corporation Q1 2026 Financial Results: Revenue, Net Loss, and SEC Filing Insights - Minichart
symbol__ Stock Quote Price and Forecast - CNN
Geron: Q1 Earnings Snapshot - theheraldreview.com
GERN Technical Analysis | Trend, Signals & Chart Patterns | GERON CORP (NASDAQ:GERN) - ChartMill
[10-Q] GERON CORP Quarterly Earnings Report - Stock Titan
Geron Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Geron Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Geron Q1 2026 shows revenue growth, stock rises - Investing.com
Geron Corp. (NASDAQ:GERN) Beats Q1 Estimates as RYTELO Sales Momentum Continues - ChartMill
Geron Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates - Yahoo! Finance Canada
GERON ($GERN) Releases Q1 2026 Earnings - Quiver Quantitative
$341M cash and $51.8M Q1 sales keep Geron on its 2026 path - Stock Titan
MSN Money - MSN
Geron earnings loom: Can RYTELO revenue sustain commercial momentum? By Investing.com - Investing.com Canada
Geron executives line up two healthcare investor conference talks - Stock Titan
Earnings Preview: Geron to Report Financial Results Pre-market on May 06 - 富途牛牛
GERN News | GERON CORP (NASDAQ:GERN) - ChartMill
Geron (GERN) to Release Earnings on Wednesday - MarketBeat
Geron (NASDAQ:GERN) Stock Price Passes Above 200-Day Moving AverageWhat's Next? - MarketBeat
Geron Corporation (GERN) Appoints Timothy Williams as EVP, Chief Legal Officer - Insider Monkey
Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026 - ChartMill
GERN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Form 4Statement of changes in beneficial ownership of securities - ADVFN
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ChartMill
Geron (NASDAQ:GERN) Stock Price Down 5.1%Here's What Happened - MarketBeat
Nine new Geron hires receive options at $1.68 a share - Stock Titan
Geron Corporation (NASDAQ:GERN) Short Interest Up 21.3% in March - MarketBeat
Geron Corporation (NASDAQ:GERN) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Geron (GERN) grants 2.5M stock options to chief legal officer - Stock Titan
Geron (GERN) EVP and Chief Legal Officer files initial Form 3 insider report - Stock Titan
Geron Adds Chief Legal Officer As Equity Ties To Execution Risk - Yahoo Finance
Geron Corp stock (US3741631036): Is imetelstat approval the real test for biotech upside? - AD HOC NEWS
New Geron legal chief gets option to buy 2.5M shares at $1.73 - Stock Titan
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Geron Highlights RYTELO Launch, 2026 Revenue Outlook and Phase 3 Myelofibrosis Plans at Needham Conf - MarketBeat
Geron names Timothy Williams as chief legal officer By Investing.com - Investing.com South Africa
Geron names Timothy Williams as chief legal officer - Investing.com
Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary - ChartMill
Geron Corp stock (US3741631036): Is imetelstat approval the real test for biotech investors now? - AD HOC NEWS
History Review: Can Geron Corporation be the next market leader2026 Key Lessons & Risk Managed Investment Signals - baoquankhu1.vn
GERN Stock Grinds Sideways As Traders Watch Biotech Breakout Levels - StocksToTrade
GERN Stock Price, Quote & Chart | GERON CORP (NASDAQ:GERN) - ChartMill
Aberdeen Group plc Boosts Stock Holdings in Geron Corporation $GERN - MarketBeat
Board agenda in new Geron (NASDAQ: GERN) 2026 virtual annual meeting proxy - Stock Titan
Geron Corporation (GERN) stock price, news, quote and history - Yahoo Finance UK
Geron Corporation (GERN) Stock Price, News, Quote & History - Yahoo! Finance Canada
[ARS] GERON CORP SEC Filing - Stock Titan
Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Geron Board Expansion Bolsters Blood Cancer Drug Rollout - timothysykes.com
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
11.97%
3.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):